Ongoing weight management with GLP-1 maintenance dosing supports long-term metabolic health
Advances in the incretin-based therapies During the previous decade, the enhancement of incretin-based therapy was observed in its effectiveness and clinical use
Dual peptides for the treatment of obesity Tirzepatide, a novel dual GIP and GLP-1RA, offers significant insights into its mechanism of action, therapeutic benefits, and clinical applications for the management of T2D and obesity in general practice
The male subjects also showed increases in lean body mass, averaging 1.26kg (nearly 3lb), but body fat percentages were unchanged.12 Viewed together, the three studies imply that sermorelin has real but perhaps limited potential as a fat burner and muscle builder
We delve deeply into the underlying science of these mechanisms and utilize this knowledge to create effective treatment plans
The goal is not simply to lose weight